{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:50:28Z","timestamp":1790869828918,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T00:00:00Z","timestamp":1189987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T00:00:00Z","timestamp":1189987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1038\/sj.bmt.1705849","type":"journal-article","created":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T10:49:43Z","timestamp":1190026183000},"page":"973-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma"],"prefix":"10.1038","volume":"40","author":[{"given":"T Y","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S G","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J W","family":"Sweetenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,17]]},"reference":[{"key":"BF1705849_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997; 89: 3909\u20133918 (0006-4971 (Print)).","journal-title":"Blood"},{"key":"BF1705849_CR2","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002770000163","volume":"79","author":"M Feuring-Buske","year":"2000","unstructured":"Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group. Ann Hematol 2000; 79: 493\u2013500.","journal-title":"Ann Hematol"},{"key":"BF1705849_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417\u20131423.","journal-title":"Blood"},{"key":"BF1705849_CR5","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BF1705849_CR6","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB . The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41\u201355.","journal-title":"Biometrika"},{"key":"BF1705849_CR8","unstructured":"Parson LS . Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference; 2001."},{"issue":"Suppl 2","key":"BF1705849_CR9","first-page":"S11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita Jr VT . The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25 (Suppl 2): S11\u2013S16.","journal-title":"Semin Hematol"},{"key":"BF1705849_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 1997; 15: 1110\u20131117.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516\u2013522 (1474-547X (Electronic)).","journal-title":"Lancet"},{"key":"BF1705849_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140\u2013147.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR13","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","volume":"94","author":"AS Freedman","year":"1999","unstructured":"Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325\u20133333.","journal-title":"Blood"},{"key":"BF1705849_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","volume":"18","author":"J Apostolidis","year":"2000","unstructured":"Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527\u2013536.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR15","first-page":"52","volume":"16","author":"A Hagenbeek","year":"2006","unstructured":"Hagenbeek A, Van Glabbeke M, Teodorovic I . The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial (Abstract). Annals of Oncology 2006; 16: 52\u201361.","journal-title":"Annals of Oncology"},{"key":"BF1705849_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460\u20131468.","journal-title":"J Clin Oncol"},{"key":"BF1705849_CR17","first-page":"300","volume":"106","author":"B Pohlman","year":"2005","unstructured":"Pohlman B, Rybicki L, Kuczkowski E, Bolwell B . Final analysis of a randomized, phase III, trial using etoposide and G-CSF with or without rituximab for peripheral stem cell mobilization in B-cell non-Hodgkins lymphoma. Blood (ASH Annual Meeting Abstracts) 2005; 106: 300.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BF1705849_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/jco.2004.22.14_suppl.6502","volume":"22","author":"HS Hochster","year":"2004","unstructured":"Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR et al. Results of E1496: a phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma (Abstract). J Clin Oncol 2004; 22: 558\u20136502.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705849.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705849","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705849.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:34:18Z","timestamp":1648082058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,17]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["BF1705849"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705849","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,17]]},"assertion":[{"value":"28 March 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}